Methylene Blue Uses: From FDA-Approved to Emerging Longevity Science

Few molecules in medicine have lived as many lives as methylene blue. Synthesized in 1876 by Heinrich Caro as a textile dye, it became one of the first synthetic drugs ever used in humans, treating malaria in the 1890s before penicillin, before cortisol, before any of the pharmacological categories that define modern medicine existed. Today, a century and a half later, methylene blue uses span FDA-approved psychiatric emergencies, standard-of-care surgical procedures, off-label infections, and a rapidly expanding frontier of mitochondrial medicine and longevity research. That range, from a dye factory in Germany to the forefront of neuroscience, is not a historical coincidence. It reflects something fundamental about what this molecule actually does inside the human body.

Methylene blue's clinical renaissance is being driven by a growing appreciation of its mechanism: the molecule functions as a redox cycler, meaning it can accept and donate electrons with unusual efficiency, effectively acting as an artificial electron carrier inside the mitochondria, the organelles responsible for generating virtually all of the cell's energy currency, adenosine triphosphate (ATP). In an era when mitochondrial dysfunction has emerged as a unifying feature of aging, neurodegeneration, and metabolic disease, a molecule that can rescue electron flow has obvious appeal. But enthusiasm must be tempered by evidence. Some methylene blue uses are backed by decades of randomized trial data; others rest on compelling mechanistic logic and animal models that have yet to translate cleanly to humans. This article maps the full landscape, distinguishing what is established from what is emerging and what remains speculative.

The Chemistry That Makes Methylene Blue Unusual

To understand why methylene blue does so many things in so many tissues, it helps to understand what makes it chemically singular. Methylene blue is a phenothiazine dye with a tricyclic ring structure that allows it to exist in two interconvertible states: an oxidized blue form and a reduced, colorless form called leucomethylene blue. This cycle between oxidized and reduced states means the molecule can donate electrons to one partner and accept them from another, essentially acting as a mobile molecular shuttle in cellular redox circuits, the biochemical processes that move electrons between molecules to generate energy or neutralize reactive oxygen species.

This redox flexibility allows methylene blue to interact with multiple enzymatic systems simultaneously. It can accept electrons from NADH and NADPH, two critical electron carriers in cellular metabolism, and donate them directly to cytochrome c, a protein in the mitochondrial electron transport chain. Think of the electron transport chain as a factory assembly line that converts food-derived electrons into usable energy. When one station on the line breaks down, production halts. Methylene blue can bypass broken stations by carrying electrons around the blockage, keeping the line moving even when the normal machinery is compromised [1]. This bypass capacity is the molecular basis for nearly every clinical application the drug has found.

Methylene blue also crosses the blood-brain barrier with unusual ease, accumulates preferentially in mitochondria-rich tissues including neurons, cardiac muscle, and liver, and is eliminated through urine, which it famously turns blue-green, a side effect that is harmless but usefully confirms absorption [2]. Its pharmacokinetics are well-characterized at low doses but become more complex at higher doses, where pro-oxidant effects begin to emerge, a nuance that is central to understanding why dosing in emerging protocols is treated with considerable care.

FDA-Approved Uses: Where the Evidence Is Unambiguous

Methylene blue holds two firm FDA approvals, and both are grounded in the same core mechanism: rescuing cells from electron transport failure.

The first is the treatment of methemoglobinemia, a condition in which the iron in hemoglobin is oxidized from its functional ferrous state (Fe²+) to a non-functional ferric state (Fe³+), preventing red blood cells from carrying oxygen. Left untreated, methemoglobinemia causes tissue hypoxia that can be rapidly fatal. Methylene blue reverses this by activating the enzyme NADPH-methemoglobin reductase, which reduces the oxidized iron back to its oxygen-carrying form [3]. In emergency medicine, intravenous methylene blue at 1 to 2 mg/kg is the standard of care for this condition, with a response rate that can be visible within minutes. The reversal is, by the standards of emergency pharmacology, spectacular.

The second approved use is as an adjunct to vasopressor therapy in refractory vasoplegic shock, a life-threatening state of extreme low blood pressure that occurs in some patients after cardiac surgery or severe sepsis. In vasoplegic shock, nitric oxide signaling becomes dysregulated, causing blood vessels to dilate catastrophically and fail to respond to standard vasopressors. Methylene blue inhibits guanylate cyclase, the enzyme that produces the secondary messenger cGMP downstream of nitric oxide, effectively putting the brakes on runaway vasodilation [4]. Multiple randomized controlled trials have confirmed that methylene blue reduces vasopressor requirements and may improve mortality in this patient population, though the evidence base is still maturing relative to older cardiovascular agents [4].

In emergency medicine, intravenous methylene blue at 1 to 2 mg/kg is the standard of care for methemoglobinemia, with a response visible within minutes — one of the most reliable acute reversals in pharmacology.

These two approvals are relevant to the broader discussion of methylene blue uses because they establish a critical point: this is not a supplement or a fringe compound. It is a drug with a well-understood mechanism, a documented safety profile at therapeutic doses, and a track record in high-stakes clinical environments. That foundation matters when evaluating the less-established applications that follow.

Psychiatry: Serotonin Toxicity and the MAO Inhibitor Problem

One of the least intuitive methylene blue uses is also one of the most clinically important: its role in causing, and under specific circumstances treating, serotonin toxicity, a potentially fatal excess of serotonergic signaling in the central nervous system.

Methylene blue is a potent, albeit reversible, inhibitor of monoamine oxidase A (MAO-A), the enzyme responsible for breaking down serotonin, dopamine, and norepinephrine in the brain. This property was not widely appreciated until case reports in the early 2000s documented serotonin syndrome in patients who received intravenous methylene blue intraoperatively while also taking serotonergic medications, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) [5]. The FDA issued a drug safety communication in 2011 warning against this combination, and it remains a critical contraindication for any methylene blue protocol [5].

The MAO-A inhibition that creates this risk also explains why methylene blue has been investigated as a treatment for depression and anxiety. Early clinical trials, including a randomized controlled trial by Narsapur and Naylor in 1983, demonstrated antidepressant effects at low doses, and subsequent research has explored methylene blue as a standalone or adjunct treatment for bipolar disorder, where MAO inhibition may help stabilize mood cycling [6]. A 2000 review by Naylor and colleagues, drawing on decades of clinical experience, concluded that methylene blue at doses of 15 mg per day produced meaningful mood stabilization in patients with bipolar disorder without the side effect burden of conventional mood stabilizers [6].

This psychiatric literature is genuinely interesting but must be contextualized carefully. The trials are small, methodologically dated by modern standards, and the mechanism is shared with conventional MAO inhibitor antidepressants, a class largely displaced by newer drugs because of their dietary and drug interaction risks. The psychiatric applications of methylene blue remain investigational and carry the same interaction profile that makes conventional MAOIs challenging to use in clinical practice.

Urinary Tract Infections: A Decades-Old Antimicrobial Tool Revisited

Methylene blue's antimicrobial properties are among its oldest documented clinical uses and among the most recently renewed in interest. In the early twentieth century, before sulfa drugs and antibiotics, methylene blue was prescribed for urinary tract infections based on empirical observation that it concentrated in urine and appeared to inhibit bacterial growth. That observation has since been mechanistically explained: methylene blue generates reactive oxygen species under light exposure and, even in the dark, disrupts bacterial electron transport chains in a manner that Gram-negative bacteria appear particularly vulnerable to [7].

The contemporary relevance is antibiotic resistance. As multidrug-resistant uropathogens including extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli become increasingly prevalent, the search for non-antibiotic antimicrobial strategies has intensified. In vitro studies have demonstrated that methylene blue, particularly when combined with photodynamic therapy (activation by red light), achieves bactericidal concentrations against resistant strains at doses achievable in urine [7]. Several European clinical centers have begun investigating oral methylene blue for recurrent urinary tract infections, with early results suggesting meaningful reduction in recurrence rates [8].

The caveat here is that robust randomized controlled trial data specifically for urinary tract infections remains limited. The mechanistic and in vitro evidence is solid; the clinical translation, while promising, is still in early phases. Clinicians prescribing methylene blue off-label for recurrent urinary tract infections are working ahead of the clinical trial evidence, a fact that should inform how patients and practitioners frame expectations.

Cognition and Memory: The Neuroscience Behind the Hype

Of all current methylene blue uses attracting scientific and public attention, its effects on cognition and memory are generating the most intense research interest. The mechanistic rationale is compelling: neurons are among the most metabolically demanding cells in the body, consuming roughly 20% of the body's oxygen supply despite comprising only 2% of its mass. Anything that boosts mitochondrial efficiency in neurons has obvious potential to improve cognitive function, and methylene blue's capacity to enhance electron transport chain activity has been demonstrated in multiple neural models [1].

The most rigorous human evidence comes from a 2016 randomized, double-blind, placebo-controlled trial by Talat Bhatt and colleagues at the University of Texas Health Science Center, which examined the effects of a single low dose of methylene blue (280 mg, approximately 4 mg/kg) on functional MRI (fMRI) brain activation and psychomotor performance in healthy adults. The methylene blue group showed significantly increased response efficiency in neural circuits associated with working memory and sustained attention, along with measurable improvements in delayed recall, a metric sensitive to hippocampal function [9]. The fMRI findings suggested that methylene blue was increasing the metabolic efficiency of neural circuits rather than simply stimulating them, a mechanistically plausible distinction that distinguishes it from conventional stimulants.

A 2016 randomized controlled trial found that a single low dose of methylene blue increased response efficiency in working memory circuits and improved delayed recall, suggesting metabolic enhancement rather than simple neural stimulation.

Animal studies extend this picture considerably. Rodent experiments have demonstrated that low-dose methylene blue enhances long-term memory consolidation, reduces age-related cognitive decline, and improves performance on spatial memory tasks, effects attributed to increased cytochrome c oxidase activity in the hippocampus [10]. The dose-response relationship in these studies is unusually shaped: an inverted U-curve, where low doses enhance and high doses impair cognitive function. This reflects the shift from antioxidant to pro-oxidant behavior at higher concentrations, an important pharmacological insight that informs why low-dose protocols are favored in clinical practice.

The cognitive effects of methylene blue are also being explored in the context of fear memory and post-traumatic stress disorder (PTSD). A randomized controlled trial published in 2017 by Zoellner and colleagues examined methylene blue as an augmentation strategy for exposure therapy in PTSD, finding that patients who received methylene blue immediately after exposure sessions showed significantly better retention of fear extinction memory at follow-up compared to placebo [11]. The hypothesis is that methylene blue enhances the consolidation of extinction memories, essentially helping the brain learn that a feared stimulus is safe, by improving the metabolic efficiency of the neural circuits that encode this new learning. This application represents one of the most intriguing intersections of methylene blue's mitochondrial mechanism and clinical psychiatry.

Neurodegeneration: Alzheimer's, Parkinson's, and the Tau Connection

The most ambitious clinical application of methylene blue is in neurodegenerative disease, particularly Alzheimer's disease, where it has been investigated as a tau aggregation inhibitor. Tau is a protein that normally stabilizes the microtubule scaffolding inside neurons. In Alzheimer's disease, tau becomes hyperphosphorylated and misfolds, forming tangled aggregates called neurofibrillary tangles that disrupt neuronal function and eventually kill cells. Methylene blue was found to inhibit tau aggregation in vitro and to reduce tau pathology in transgenic mouse models of Alzheimer's disease, prompting significant pharmaceutical investment [12].

The clinical results have been mixed, a common theme in Alzheimer's drug development. TRx0237, a derivative of methylene blue developed by TauRx Pharmaceuticals, failed to meet its primary endpoints in a large Phase III trial published in 2016, though post-hoc analyses suggested possible benefit in patients not also taking acetylcholinesterase inhibitors [13]. The parent compound, methylene blue itself, has shown more consistent effects at lower doses in preclinical models, and several research groups continue to investigate its role in Alzheimer's prevention and early-stage intervention rather than treatment of established disease [10].

In Parkinson's disease, methylene blue's mitochondrial rescue mechanism is particularly relevant because the dopaminergic neurons of the substantia nigra, the cells that degenerate in Parkinson's disease, have an unusually high metabolic demand and appear especially vulnerable to mitochondrial dysfunction. In rodent models of Parkinson's disease induced by the mitochondrial toxin MPTP, methylene blue administration significantly protected dopaminergic neurons and preserved motor function [14]. Human trials in this indication are in early stages, but the mechanistic rationale is well-grounded in the established pathophysiology of the disease.

Mitochondrial Medicine: The Longevity Angle

The longevity research community has focused on methylene blue primarily through the lens of mitochondrial health, and for good reason. Mitochondrial dysfunction is one of the hallmarks of aging identified by López-Otín and colleagues in their landmark 2013 Cell paper, and it sits upstream of several other aging mechanisms including chronic inflammation, cellular senescence, and stem cell exhaustion [15]. As mitochondria age, their efficiency declines, electron leakage increases, and the resulting excess of reactive oxygen species creates a feedback loop of oxidative damage that accelerates cellular aging throughout the body.

Methylene blue addresses this problem directly. By accepting electrons that would otherwise leak from the electron transport chain and generate superoxide, it reduces mitochondrial oxidative stress. Simultaneously, by facilitating electron flow in compromised mitochondria, it maintains ATP production in cells where normal electron transport is impaired. This dual action, reducing damage while preserving energy output, is the molecular basis for interest in methylene blue as a longevity-oriented intervention [1].

In fibroblast cell cultures derived from elderly donors, methylene blue treatment has been shown to reverse multiple markers of cellular aging, including mitochondrial membrane potential, oxygen consumption rate, and morphological changes associated with senescence [16]. The cells treated with methylene blue looked, metabolically, more like young cells. In animal models, chronic low-dose methylene blue administration has extended lifespan in invertebrate models and improved physical performance and metabolic markers in aged rodents [17]. Whether these effects translate to meaningful healthspan extension in humans remains an open question, but it is being actively investigated.

In fibroblast cultures from elderly donors, methylene blue reversed multiple markers of cellular aging — restoring mitochondrial membrane potential and oxygen consumption to profiles resembling younger cells.

The mitochondrial effects of methylene blue intersect with broader longevity protocols in ways that are clinically meaningful. Mitochondrial dysfunction accelerates many of the same processes targeted by established longevity interventions: autophagy, the cellular recycling process promoted by rapamycin and fasting; AMPK activation, the energy-sensing pathway targeted by metformin and exercise; and NAD+ metabolism, which declines with age and affects sirtuin activity. Methylene blue operates through a complementary but distinct mechanism, making it a candidate for combination protocols rather than a standalone intervention. Clinicians at longevity-focused practices sometimes consider methylene blue alongside other mitochondrial-targeted approaches as part of a broader Longevity Optimization framework, though the evidence base for combination approaches specifically is still nascent.

Long COVID and Fatigue Syndromes: An Emerging Hypothesis

Among the newest and most discussed methylene blue uses is its potential application in long COVID and related post-viral fatigue syndromes, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The connection is mechanistic: emerging evidence suggests that a subset of long COVID pathology involves mitochondrial dysfunction in tissues including the brain, skeletal muscle, and vascular endothelium, producing the fatigue, cognitive impairment (colloquially termed "brain fog"), and exercise intolerance that characterize the syndrome [18].

A striking early case series published in 2021 reported complete or near-complete resolution of long COVID symptoms, including profound fatigue and brain fog, in a small group of patients treated with low-dose oral methylene blue [19]. The sample size, fewer than ten patients, precludes any clinical conclusions, but the mechanistic plausibility prompted several research groups to initiate controlled trials. At the time of writing, results from adequately powered randomized trials in long COVID are not yet available, and this application should be considered experimental. The hypothesis is scientifically credible; the evidence is not yet sufficient to guide clinical decisions.

The long COVID angle illustrates a broader pattern in methylene blue research: mechanistic logic consistently runs ahead of clinical trial data. The gap between compelling rationale and robust evidence is not a reason to dismiss the science, but it is a reason to distinguish between what the molecule can do in controlled experimental conditions and what has been demonstrated to help real patients in randomized trials.

Antimicrobial Photodynamic Therapy: Light-Activated Uses

An entirely distinct category of methylene blue uses involves photodynamic therapy (PDT), a technique in which a photosensitizing agent is applied to tissue and then activated by light of a specific wavelength, generating reactive oxygen species that destroy targeted cells or organisms. Methylene blue is one of the most commonly used photosensitizers for antimicrobial PDT because of its favorable absorption spectrum (red light, around 660 nm), low cost, and well-characterized safety profile.

The oral health applications of methylene blue PDT are among the best evidenced in this category. Multiple systematic reviews and meta-analyses have demonstrated that methylene blue PDT significantly reduces periodontal pathogens including Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans when used as an adjunct to conventional scaling and root planing, the standard non-surgical treatment for periodontitis [20]. Given the established association between periodontitis, systemic inflammation, cardiovascular disease, and accelerated biological aging, this application has direct relevance to longevity medicine, though it is largely practiced within dentistry rather than internal medicine.

Methylene blue PDT has also been investigated for wound healing, particularly in chronic wounds where biofilm-forming bacteria resist conventional antibiotics. In vitro and early clinical studies suggest meaningful antibiofilm activity, and the approach is being evaluated in several surgical and dermatological contexts [21]. The light-activation requirement limits these applications to accessible tissues, but the mechanism is distinct from systemic methylene blue use and carries a different safety profile.

Cancer: Preclinical Promise and Clinical Caution

Methylene blue's effects on mitochondrial function and reactive oxygen species generation have also attracted attention in oncology, where the metabolic vulnerabilities of cancer cells represent potential therapeutic targets. Cancer cells frequently exhibit the Warburg effect, a preferential reliance on glycolysis for energy production even in the presence of oxygen, a metabolic shift that leaves them vulnerable to interventions that disrupt electron transport or increase mitochondrial oxidative stress [22].

In laboratory models, methylene blue has demonstrated selective cytotoxicity against multiple cancer cell lines, including breast, colon, and ovarian cancer cells, at concentrations that are less toxic to normal cells [2]. The photodynamic therapy application extends to oncology as well, where methylene blue PDT is being investigated for bladder cancer, head and neck cancers, and other tumors accessible to light delivery. A small clinical trial in superficial bladder cancer reported meaningful tumor response rates with intravesical methylene blue PDT [23].

These findings are genuinely interesting but must be contextualized firmly within the preclinical stage. Cancer therapy involves complex tumor biology, immune interactions, and systemic effects that in vitro and animal models frequently fail to predict. No clinical-grade evidence yet supports methylene blue as a standalone cancer treatment, and its interaction profile with chemotherapy agents is not fully characterized. The oncological applications are worth watching, not yet worth acting on outside of controlled trial settings.

Dosing, Safety, and the Hormetic Curve

The safety profile of methylene blue is one of its more nuanced features, governed by a principle that pharmacologists call hormesis: the phenomenon in which a substance produces beneficial effects at low doses and harmful effects at higher doses. This is not unique to methylene blue, but the dose-response relationship is unusually steep and the mechanistic explanation unusually clear. At low doses, typically defined as below 1 mg/kg per day in most research protocols, methylene blue acts predominantly as an antioxidant and metabolic enhancer. At higher doses, it becomes a pro-oxidant, generating rather than neutralizing reactive oxygen species [1].

The most serious safety concern is serotonin toxicity when methylene blue is combined with serotonergic drugs, particularly SSRIs and SNRIs, a contraindication supported by case series and formal FDA warnings [5]. This interaction is dose-dependent but not safely dose-titrated around at clinical doses, making concurrent use of methylene blue and serotonergic medications a hard contraindication in standard protocols. Patients on SSRIs, SNRIs, tramadol, linezolid, or other MAO-influencing drugs must discuss this risk with a prescribing clinician before any methylene blue protocol.

Additional considerations include G6PD deficiency, an inherited enzyme deficiency in which methylene blue not only fails to treat methemoglobinemia but paradoxically worsens it by generating hemolytic anemia. Glucose-6-phosphate dehydrogenase (G6PD) screening is standard practice before initiating any methylene blue protocol. The drug is also contraindicated in known hypersensitivity, and its use in pregnancy carries theoretical risk given its ability to cross placental and blood-brain barriers [3].

At established low doses for cognitive or longevity applications, typically 0.5 to 4 mg/kg per day in research protocols, the documented adverse effects include urine discoloration (universal, harmless), potential for mild nausea at higher end of dose range, and transient headache in some users. Long-term safety data at these doses in healthy populations is limited but has not flagged serious signals in the existing literature. The prudent approach is clinical supervision, baseline assessment for contraindications, and conservative dose titration, exactly the framework applied to any emerging pharmacological intervention. Healthspan's Methylene Blue protocol follows this model, with prescriber oversight and individualized dosing.

The Regulatory and Evidence Landscape

Methylene blue occupies an unusual regulatory position. It is an FDA-approved prescription drug for methemoglobinemia and an adjunct in vasoplegic shock, meaning it is not a supplement and is not legally available without a prescription in the United States. Off-label prescribing of FDA-approved drugs is legal and common in medicine, but it places the burden of evidence assessment firmly on the prescribing clinician. The enthusiastic off-label market for methylene blue has generated a parallel market in unregulated formulations, sold in some jurisdictions as supplements or research chemicals. These products vary enormously in purity, and pharmaceutical-grade methylene blue suitable for human consumption is distinct from industrial-grade dye, a distinction that matters for both safety and efficacy.

The evidence hierarchy for methylene blue uses, as of the current literature, looks approximately like this. The tier-one evidence, supported by multiple randomized controlled trials and FDA approval, covers methemoglobinemia treatment and vasoplegic shock. The tier-two evidence, supported by at least one rigorous randomized controlled trial, covers PTSD extinction memory augmentation and potentially cognitive enhancement in healthy adults. The tier-three evidence, supported by compelling mechanistic data and animal studies with limited human data, covers Alzheimer's disease, Parkinson's disease, longevity and anti-aging applications, long COVID, and antimicrobial uses beyond periodontitis. The periodontitis PDT application sits closer to tier two based on meta-analytic dental literature.

This tiered view is not a dismissal of the emerging applications. It is an accurate map of where the science stands, which is the essential starting point for making informed clinical decisions. The mechanistic coherence of methylene blue's effects across these domains is genuinely striking, and the research pipeline is active. Several ongoing trials, including NCT studies registered at ClinicalTrials.gov, are evaluating methylene blue in Alzheimer's prevention, long COVID, and age-related cognitive decline. The next five years are likely to substantially redefine which applications move from tier-three to tier-two status.

Putting Methylene Blue in the Context of Longevity Medicine

For clinicians and patients operating within a longevity medicine framework, methylene blue occupies a specific niche. It is not a replacement for the foundational pillars of healthspan: structured exercise, protein-adequate nutrition, sleep optimization, and metabolic health management. It is also not analogous to the longevity pharmaceuticals with the strongest human epidemiological data, such as metformin or rapamycin, where large population datasets and interventional studies provide a more robust evidence foundation. Rather, methylene blue is best understood as a mitochondrial-targeted intervention with a credible mechanism, a well-understood safety profile at low doses, an FDA-approved parent application, and a growing body of evidence in cognitive and neurological domains.

The patients for whom methylene blue is most clearly relevant in a longevity context are those with documented mitochondrial dysfunction, age-related cognitive decline, post-viral fatigue syndromes, or recurrent urinary tract infections where antibiotic resistance is a concern. In each case, the mechanism-to-indication fit is tight, and the risk-benefit ratio at low doses and without concurrent serotonergic medications is favorable. Beyond these groups, the longevity application is genuinely investigational: the biology is compelling, the safety at low doses appears acceptable, and the decision to use it represents a thoughtful weighing of mechanistic evidence against the absence of long-term human outcome data.

Methylene blue also fits naturally alongside other mitochondrial-focused interventions. Compounds that support mitochondrial biogenesis, the creation of new mitochondria, or mitophagy, the selective clearance of damaged mitochondria, address complementary aspects of the same aging biology. The Mitophagy Formula and the Cellular Renewal Stack represent approaches that target these adjacent mechanisms, and the conceptual case for combining mitophagy support with a mitochondrial electron transport enhancer like methylene blue is mechanistically coherent, even if combination outcome data in humans remains to be generated.

What the Next Chapter Looks Like

The trajectory of methylene blue research follows a recognizable pattern in medicine: an old drug with a known mechanism acquires new relevance as scientific understanding catches up to its observed effects. Aspirin followed this path, as did lithium and metformin. The compounds that survive this reexamination typically do so because their mechanisms are fundamental rather than incidental, because they act on biology that turns out to be more central to disease and aging than initially appreciated.

Mitochondrial dysfunction fits that description precisely. As the field has deepened its understanding of how mitochondrial decline drives not just metabolic disease but neurodegeneration, immune dysregulation, and cellular aging, a molecule that can maintain mitochondrial function under duress looks increasingly valuable. The questions that remain are questions of magnitude and translation: how much benefit does methylene blue confer in humans at the doses that are safe, across which conditions, over what time horizon, and in combination with which other interventions?

The answers are coming. In the meantime, the honest position is that methylene blue is a molecule with a legitimate and expanding role in medicine, a chemical history that spans nearly 150 years without exhausting its clinical relevance, and a mechanistic profile that sits squarely at the intersection of the most important biological questions in longevity science. Understanding what it actually does, and what the evidence actually shows, is the prerequisite for using it wisely.